Wednesday, 22 May 2024

Australia deals with AstraZeneca for AZD1222 COVID-19 investigational vaccine

07 September 2020 | News

Australia announces a deal for 84 million vaccine doses

Photo Credit: Freepik

Photo Credit: Freepik

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, as a potential candidate for an emergency use authorization (EUA) via the U.S. Food and Drug Administration (FDA) through the Phase 3  clinical trials findings point to significant efficacy and safety. Australia is positioning itself to receive the first doses of the investigational product, originally developed by University of Oxford. Australia approved a second vaccine purchase involving 26 million doses to be manufactured locally by CSL.

The Australian Government has made a $1.7bn AUD ($1.34bn USD) supply and production agreement for COVID-19 vaccines: with the first doses set to come from AstraZeneca’s vaccine in January 2021.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account